Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
STUDY OBJECTIVES
Primary:
To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem
cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects
with mild to moderate dementia due to Alzheimer's disease.
Secondary:
To assess the preliminary efficacy of hMSCs versus placebo in subjects with
Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric
endpoints.